Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced Cancer

2005225 citationsJournal Article

Authors

Anne Thomas · Novartis (Germany)

Bruno Morgan · Novartis (Germany)

Mark A. Horsfield · Novartis (Germany)

Anthony Higginson · Novartis (Germany)

Andrea Kay · Novartis (Germany)

Lucy Lee · Novartis (Germany)

Eric Masson · Novartis (Germany)

Abstract

The maximum-tolerated oral dose of PTK/ZK is 750 mg orally bid. DCE-MRI and pharmacokinetic data indicate that PTK/ZK >/= 1,000 mg total daily dose is the biologically active dose.

Topics & Keywords

Angiogenesis and VEGF in Cancer Cancer Treatment and Pharmacology Cancer, Hypoxia, and Metabolism

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 23, Issue 18, pp. 4162-4171

DOI: 10.1200/jco.2005.09.034

Field-Weighted Citation Impact: 13.04